Loading clinical trials...
Loading clinical trials...
A Phase 3 Randomized, Double-blinded, Active-controlled, Multicenter Trial to Evaluate the Safety and Efficacy of Fabagal® (Agalsidase Beta) in Patients With Fabry Disease
Conditions
Interventions
Fabagal® (Agalsidase beta)
Active comparator (Agalsidase beta)
Locations
3
Philippines
Philippine General Hospital
Manila, Philippines
St.Luke's Medical Center
Manila, Philippines
Seoul Asan Center
Seoul, Songpa-gu, South Korea
Start Date
April 14, 2023
Primary Completion Date
June 1, 2025
Completion Date
December 1, 2025
Last Updated
July 29, 2024
NCT07382128
NCT05923788
NCT07277361
NCT04252066
NCT06776419
NCT05629559
Lead Sponsor
ISU Abxis Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions